|23.27||-0.1900||-0.81%||Vol 178.72K||1Y Perf 22.87%|
|Apr 16th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||31.13||Analyst Rating||Strong Buy 1.30|
|Potential %||33.78||Finscreener Ranking||★★★+ 53.30|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★+ 48.83|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★★ 69.68|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Market Cap||819.20M||Earnings Rating||Strong Sell|
|Price Range Ratio 52W %||67.64||Earnings Date||6th May 2021|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||6th May 2021|
|Estimated EPS Next Report||0.29|
|EPS Growth Next 5 Years %||20.00|
|Avg. Weekly Volume||203.26K|
|Avg. Monthly Volume||277.94K|
|Avg. Quarterly Volume||582.29K|
Collegium Pharmaceutical Inc. (NASDAQ: COLL) stock closed at 23.27 per share at the end of the most recent trading day (a -0.81% change compared to the prior day closing price) with a volume of 179.88K shares and market capitalization of 819.20M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 234 people. Collegium Pharmaceutical Inc. CEO is Joseph J. Ciaffoni.
The one-year performance of Collegium Pharmaceutical Inc. stock is 22.87%, while year-to-date (YTD) performance is 16.18%. COLL stock has a five-year performance of 25.51%. Its 52-week range is between 15.66 and 26.91, which gives COLL stock a 52-week price range ratio of 67.64%
Collegium Pharmaceutical Inc. currently has a PE ratio of 30.30, a price-to-book (PB) ratio of 4.36, a price-to-sale (PS) ratio of 3.44, a price to cashflow ratio of 8.60, a PEG ratio of 2.32, a ROA of 5.47%, a ROC of 11.79% and a ROE of 19.03%. The company’s profit margin is 11.66%, its EBITDA margin is 28.50%, and its revenue ttm is $233.50 Million , which makes it $6.63 revenue per share.
Of the last four earnings reports from Collegium Pharmaceutical Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $0.29 for the next earnings report. Collegium Pharmaceutical Inc.’s next earnings report date is 06th May 2021.
The consensus rating of Wall Street analysts for Collegium Pharmaceutical Inc. is Strong Buy (1.3), with a target price of $31.13, which is +33.78% compared to the current price. The earnings rating for Collegium Pharmaceutical Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Collegium Pharmaceutical Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Collegium Pharmaceutical Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 11.17, ATR14 : 1.26, CCI20 : -60.77, Chaikin Money Flow : -0.07, MACD : -0.12, Money Flow Index : 52.02, ROC : -2.39, RSI : 51.15, STOCH (14,3) : 40.34, STOCH RSI : 0.33, UO : 48.87, Williams %R : -59.66), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Collegium Pharmaceutical Inc. in the last 12-months were: Alison B. Fleming (Option Excercise at a value of $275 040), Alison B. Fleming (Sold 23 967 shares of value $519 441 ), Joseph Ciaffoni (Option Excercise at a value of $932 444), Joseph Ciaffoni (Sold 141 305 shares of value $3 110 191 ), Michael T. Heffernan (Sold 114 725 shares of value $2 599 712 ), Scott Dreyer (Option Excercise at a value of $127 200), Scott Dreyer (Sold 23 083 shares of value $545 953 ), Shirley R. Kuhlmann (Sold 13 141 shares of value $295 670 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.